{"entity":{"id":"nct04673942","kind":"trial","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","aka":[],"tldr":"A phase 2 trial of AdAPT-001 in sarcomas, run by EpicentRx, Inc., active and no longer recruiting.","summary":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors is a phase 2 interventional study registered as NCT04673942 by EpicentRx, Inc., with 140 participants enrolled, started 2021-03-29 and due to reach its primary completion in 2026-12-01. Interventions recorded: AdAPT-001 and Checkpoint Inhibitor, Immune.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04673942","url":"https://clinicaltrials.gov/study/NCT04673942"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["epicentrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04673942","phase":"2","setting":"An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors","sponsor":"EpicentRx, Inc.","enrolled":140,"outcomes":[]},"route":"/trials/nct04673942/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"company":[{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/"}]}}